

AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions and listings of claims in the application.

Listing of Claims:

1. (Previously Presented) A method of identifying a compound that inhibits binding of MUC1 to a tumor progressor, the method comprising:

(a) providing a MUC1 test agent, wherein the MUC1 test agent comprises a phosphorylated YEKV site;

(b) providing a tumor progressor test agent that binds to the phosphorylated MUC1 test agent;

(c) contacting the phosphorylated MUC1 test agent with the tumor progressor test agent in the presence of a test compound; and

(d) determining whether the test compound inhibits binding of the phosphorylated MUC1 test agent to the tumor progressor test agent.

2. (Withdrawn) The method of claim 1, wherein the tumor progressor test agent is a c-Src test agent.

3. (Withdrawn) The method of claim 1, wherein the tumor progressor test agent is a p120^{cm} test agent.

4. (Withdrawn) The method of claim 1, wherein the tumor progressor test agent is an epidermal growth factor receptor (EGF-R) test agent.

5. (Original) The method of claim 1, wherein the tumor progressor test agent is a β -catenin test agent.

6. (Withdrawn) The method of claim 1, wherein the tumor progressor test agent is a protein kinase C δ (PKC δ) test agent.

7. (Original) The method of claim 1, wherein the contacting is carried out in a cell-free system.

8. (Original) The method of claim 1, wherein the contacting occurs in a cell.

9. (Currently Amended) The method of claim 1, wherein the test compound is a peptide fragment of the tumor progressor.

10. (Withdrawn) The method of claim 9, wherein the tumor progressor test agent is a c-Src test agent.

11. (Withdrawn) The method of claim 9, wherein the tumor progressor test agent is a p120^{cas} test agent.

12. (Withdrawn) The method of claim 9, wherein the tumor progressor test agent is an epidermal growth factor receptor (EGF-R) test agent.

13. (Currently Amended) The method of claim 9, wherein the tumor progressor test agent is a β -catenin test agent and the MUC1 test agent is phosphorylated.

14. (Withdrawn) The method of claim 9, wherein the tumor progressor test agent is a protein kinase C δ (PKC δ) test agent.

15. (Previously Presented) The method of claim 9, wherein the contacting is carried out in a cell-free system.

16. (Previously Presented) The method of claim 9, wherein the contacting occurs in a cell.

17. (Previously Presented) The method of claim 1, wherein the MUC1 test agent comprises SEQ ID NO:1.

18. (Canceled).

19. (Previously Presented) The method of claim 5, wherein the MUC1 test agent comprises SEQ ID NO:1 phosphorylated at Y46.

20-21. (Canceled)

22. (Previously Presented) The method of claim 8, wherein the cell is a cancer cell.

23. (Previously Presented) The method of claim 22, wherein the cancer cell expresses MUC1.

24. (Previously Presented) The method of claim 22, wherein the cancer cell is a breast cancer cell, a lung cancer cell, a colon cancer cell, a pancreatic cancer cell, a renal cancer cell, a stomach cancer cell, a liver cancer cell, a bone cancer cell, a hematological cancer cell, a neural tissue cancer cell, a melanoma cell, an ovarian cancer cell, a testicular cancer cell, a prostate cancer cell, a cervical cancer cell, a vaginal cancer cell, or a bladder cancer cell.

25. (Previously Presented) The method of claim 5, wherein providing a phosphorylated MUC1 test agent comprises combining a MUC1 test agent, a tumor progressor test agent with kinase activity, and ~~a source of phosphate ions~~ ATP, wherein a MUC1 test agent phosphorylated at a YEKV site is formed.

26. (Currently Amended) The method of claim 25, wherein the tumor progressor test agent with kinase activity is c-src, EGF-R, or ~~PDC\$~~ PKC.

27. (Canceled)